Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha(1)-adrenergic receptor (α1-AR) is a G-protein coupled receptor that primarily mediates physiological responses to norepinephrine and epinephrine. There are three subtypes: α1A, α1B, and α1D. They couple to Gq/11 proteins, stimulating phospholipase C, leading to increased intracellular calcium and smooth muscle contraction. Drugs targeting these receptors are used for hypertension, BPH, heart failure, glaucoma, sexual dysfunctions, and some cancers. Alternative splicing can generate isoforms with different C-terminal regions.
Agonist binding stimulates phospholipase C via Gq/11, leading to increased intracellular calcium and activation of protein kinase C pathways, resulting in smooth muscle contraction and vasoconstriction. Antagonists block the receptor, preventing agonist binding and subsequent signaling.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha(1)-adrenergic receptor.